Location: Cambridge MA
Cambridge, MA-based H3 Biomedicine (H3B) is a leading company in cancer genomics driven drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million in initial funding from Eisai, plus a continued ongoing commitment to fund H3B’s robust discovery pipeline and clinical programs. Now with four clinical stage anti-cancer molecules in active development, H3B is able to uniquely leverage distinct insights from cancer genomics and real-life patient data to advance its projects to clinical proof of concept and beyond. H3B embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company, to create a prolific drug discovery engine and partnership platform.
The ideal candidate is highly motivated and possesses a Ph.D. with 5-10 year’s industrial experience in medicinal/synthetic organic chemistry. He/She is independent, motivated and experimentally skilled with a strong track record of lab results and interest in designing and synthesizing compounds. He/she independently contributes to lead generation and the creation of a unique compound collection through traditional and parallel synthesis to optimize hits and lead series toward a drug candidate. He/she should have strong communication skills, an eagerness to learn, and ability to work well in teams.
Principal Duties and Responsibilities
- Provide effective project and scientific leadership to medicinal chemistry team members.
- Design new and/or independently execute syntheses of target compounds.
- Troubleshoot and optimize multi-step synthetic routes.
- Identifies and solves significant problems related to project/discipline.
- Effectively communicates explains and presents research results across multiple disciplines
- Contribute to the preparation and submission of patents, scientific publications &/or regulatory documents.
- Leads scientific aspects of research projects to overcome barriers and make effective decisions.
- Coordinates with collaborators, consultants, and contract services to improve research projects in a transparent, timely and consistent manner.
- Maintain high standards of laboratory safety, comply with H3 safety manual, and complete required training.
- High level of performance and track record of success in the design and synthesis of bioactive compounds.
- Works in a fast-paced/small-team environment that is growing and evolving and which requires regular reprioritization of projects while adhering to timelines and achievement of deliverables.
- Evaluate and prioritize research efforts within broader team objectives.
- Work with minimal supervision and simultaneously balance multiple tasks.
- Show initiative to expand scope and depth of technical competence.
- Efficient use of scientific literature and chemical/scientific databases.
- Good interpersonal skills, flexibility and works well within a team environment.
- D. in organic chemistry with 5-10 years of industrial experience in medicinal/synthetic organic chemistry.
- Proven track record of leading medical chemistry projects from HTS leads to the delivery of high quality drug candidates as evidenced by publications and/or patents.
- Knowledgeable in all aspects of drug discovery and related disciplines.
- Strong organic and medicinal chemistry bench skills.
- Solid knowledge of synthetic organic chemistry reaction mechanisms and reactivity.
- Independently creates hypotheses and designs compounds accordingly.
- Uses contemporary medicinal chemistry principles to drive science to key decision points.
- Excellent written and verbal communication skills.
About H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately-held, uniquely-structured oncology discovery enterprise whose sole mission is to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.